PDF(Pubmed)
Abstract：
BACKGROUND: Follicular carcinoma of thyroid is a rare pathological type of thyroid carcinoma, accounting for 4.5% of the total. At present, the main treatment methods include surgery, iodine therapy, thyroid hormone inhibitors, etc. Targeted drug therapy is very important for distant metastasis and iodine-refractory differentiated thyroid cancer.
METHODS: This clinical case is a 51-year-old male patient with follicular carcinoma of thyroid.
METHODS: After 7 years of total thyroidectomy, multiple distant metastasis occurred to bilateral lungs, bones, multiple lymph nodes, etc.
METHODS: After multidisciplinary consultation in the department of oncology, thoracic surgery, nuclear medicine and other departments, he received targeted drug therapy of Lenvatinib.
RESULTS: After 3 months, his condition was partially relieved, and his quality of life was significantly improved. After 11 months of treatment, the evaluated efficacy was still in remission.
CONCLUSIONS: Late metastatic thyroid cancer is faced with dilemma of radioiodine refractory after traditional treatment. This will provide further evidence for therapeutic intervention in similar patients in the future.
METHODS: This clinical case is a 51-year-old male patient with follicular carcinoma of thyroid.
METHODS: After 7 years of total thyroidectomy, multiple distant metastasis occurred to bilateral lungs, bones, multiple lymph nodes, etc.
METHODS: After multidisciplinary consultation in the department of oncology, thoracic surgery, nuclear medicine and other departments, he received targeted drug therapy of Lenvatinib.
RESULTS: After 3 months, his condition was partially relieved, and his quality of life was significantly improved. After 11 months of treatment, the evaluated efficacy was still in remission.
CONCLUSIONS: Late metastatic thyroid cancer is faced with dilemma of radioiodine refractory after traditional treatment. This will provide further evidence for therapeutic intervention in similar patients in the future.
摘要：
背景：甲状腺滤泡癌是一种罕见的甲状腺癌病理类型，占总数的4.5%。目前,主要的治疗方法包括手术，碘治疗,甲状腺激素抑制剂，等。靶向药物治疗对于远处转移和碘难治性分化型甲状腺癌非常重要。
方法：本临床病例为一名51岁男性甲状腺滤泡状癌患者。
方法：甲状腺全切除术7年后，双肺多发远处转移,骨头,多个淋巴结,等。
方法：在肿瘤科进行多学科咨询后，胸外科,核医学和其他部门，他接受了Lenvatinib的靶向药物治疗.
结果：3个月后，他的病情得到了部分缓解，他的生活质量得到了显著改善。经过11个月的治疗，评估的疗效仍处于缓解状态.
结论：晚期转移性甲状腺癌面临传统治疗后放射性碘难治的困境。这将为将来类似患者的治疗干预提供进一步的证据。
方法：本临床病例为一名51岁男性甲状腺滤泡状癌患者。
方法：甲状腺全切除术7年后，双肺多发远处转移,骨头,多个淋巴结,等。
方法：在肿瘤科进行多学科咨询后，胸外科,核医学和其他部门，他接受了Lenvatinib的靶向药物治疗.
结果：3个月后，他的病情得到了部分缓解，他的生活质量得到了显著改善。经过11个月的治疗，评估的疗效仍处于缓解状态.
结论：晚期转移性甲状腺癌面临传统治疗后放射性碘难治的困境。这将为将来类似患者的治疗干预提供进一步的证据。
